Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation

• Published in: South African medical journal Vol. 103; no. 4; pp. 241 - 245
• Main Authors: Bergh, M, Marais, C A, Miller-Jansön, H, Salie, F, Stander, M P
• Format: Journal Article
• Language: English
• Published: South Africa Health & Medical Publishing Group 01.04.2013
• Subjects: Aged; Aged, 80 and over; Anticoagulants - economics; Anticoagulants - therapeutic use; Antithrombins - economics; Antithrombins - therapeutic use; Atrial fibrillation; Atrial Fibrillation - complications; Benzimidazoles - economics; Benzimidazoles - therapeutic use; beta-Alanine - analogs & derivatives; beta-Alanine - economics; beta-Alanine - therapeutic use; Complications and side effects; Cost-Benefit Analysis; Dabigatran; Dabigatran etexilate; Dosage and administration; Drug Costs; Drug therapy; Female; Humans; International Normalized Ratio - economics; Male; Markov Chains; Myocardial Infarction - economics; Myocardial Infarction - etiology; Myocardial Infarction - prevention & control; Prevention; Quality-Adjusted Life Years; Risk factors; South Africa; Stroke (Disease); Stroke - economics; Stroke - etiology; Stroke - prevention & control; Warfarin - economics; Warfarin - therapeutic use; South Africa
• ISSN: 0256-9574
• DOI: 10.7196/SAMJ.6471

Dabigatran is an oral anticoagulant direct thrombin inhibitor recently registered in South Africa (SA) to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation (AF). Owing to the price disparity between warfarin (the current gold standard for treatment of patients with AF) and dabigatran, we conducted an economic appraisal of the use of dabigatran compared with warfarin from a payer perspective in the South African private healthcare setting. To estimate the cost-effectiveness (CE) and budget impact of dabigatran compared with warfarin for the prevention of stroke in AF patients. Methods. A previously published Markov model was populated with SA cost and mortality data to estimate the CE and budget impact analysis of dabigatran over a lifetime horizon. The model population consisted of a cohort of patients of whom those aged younger than 80 years used dabigatran 150 mg twice daily and those older than 80 years 110 mg twice daily. Modelled outcomes included total cost, quality-adjusted life years (QALYs) and incremental CE ratio (ICER), with the effectiveness measured by QALYs gained. Dabigatran compared with warfarin as first-line treatment was estimated to have an ICER of R93 290 and an average incremental cost per beneficiary per month of R0.39 over a 5-year period. Conservative assumptions were made regarding the number of international normalised ratio monitoring tests for patients on warfarin, and the ICER is estimated to decrease by as much as 15.7% under less stringent assumptions. A robust sensitivity analysis was also performed. Dabigatran as first-line treatment compared with warfarin for the use of stroke prevention in patients with AF is deemed cost-effective when used in accordance with its registered indication in the SA private sector.